key: cord-0065263-qdqd574w
authors: Shaw, Kirsten E.; Cavalcante, João L.; Han, B Kelly; Gössl, Mario
title: Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings
date: 2021-06-16
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2021.06.002
sha: 69c13deee49efaed1afc89c71ae94b4776f686ac
doc_id: 65263
cord_uid: qdqd574w

nan

Editor's note: Why are we publishing case series raising a possible association between COVID-19 vaccination and myocarditis?

Scientific progress depends upon being open to new ideas and observations. Scientific journals help in this process by providing a platform for such observations, but only after a thoughtful scholarly scrutiny through rigorous peer review. Post-publication debates ensure further critical refinements-some observations stand the test of time while others are discarded. In that spirit, JACC Imaging is publishing 2 small case series of patients where COVID-19 vaccination was "temporally associated with development of myocarditis." Imaging data in such cases is lacking-CMR is now thought to be the closest "non-biopsy" gold standard for diagnosing myocarditis and we felt that documenting CMR findings in such suspected cases would be important.

It is critical to note that:

1. These case series raise the possibility of an association primarily based on the occurrence of myocarditis in close time proximity with COVID-19 vaccination. They do not prove that myocarditis was mediated by COVID-19 vaccination.

As the coronavirus disease 2019 (COVID-19) outbreak spread across the globe, vaccine development efforts were expedited. The United States Food and Drug Administration granted an emergent use authorization for two vaccines: the Pfizer-Bio Tech 2-dose vaccine and the Moderna 2-dose vaccine. Our knowledge regarding adverse reactions to these vaccines continues to grow. We present cardiac magnetic resonance (CMR) imaging findings in four cases of acute myocarditis that were temporally related to the receipt of COVID-19 vaccine and could raise the possibility of being associated with the vaccination. CMR imaging utilized a specific institutional imaging protocol (see below) to evaluate for the presence of myocardial edema and non-ischemic myocardial injury configuring the main criteria according to the updated Lake Louise criteria [1] . To our knowledge, this is the largest case series to date with a comprehensive timeline description (see Figure 1 ) and systematic CMR imaging evaluation of this potential adverse reaction to the COVID-19 vaccine. The fact that the two patients with prior COVID-19

infection developed symptoms following their first dose, and the two patients without prior COVID-19 infection developed symptoms following their second dose, raises interesting possibilities about a potential immune-boosting mechanism after prior immune exposure or priming.

It is important to note that our small case series, while raising the possibility of a potential association based on the close temporal relation between a clinical and CMR picture of All CMR studies were performed according to our institutional protocol for suspected myocarditis using MAGNETOM Aera 1.5 Tesla MRI scanner (Siemens Healthineers) including motion-corrected, inline T1 parametric mapping using MOLLI sequence, T2 mapping (Myomaps, Siemens Healthineers), late gadolinium enhancement imaging using free-breathing motion-corrected phase-sensitive inversion recovery sequence, 10-15 mins after single-dose (0.1 mmol/kg) of macrocyclic Gadobutrol (Gadavist®, Bayer Healthcare LLC, Whippany, NJ) and extracellular volume fraction mapping (WIP 1041B, Siemens Healthineers). Breath-held steadystate free precession cine imaging was used for all long and short-axis, with standard segmentation with semi-automated contouring. All CMR studies were independently evaluated and regions of interest drawn at the side of myocardial injury, and at the remote/healthy/uninvolved myocardium for reference.

A 24-year-old man with no previous cardiac history developed chest pain 4 days following his second dose of the Pfizer COVID-19 vaccine. He had never had a prior COVID-19 infection. He presented to the emergency department where his COVID-19 antigen testing was negative, and his troponin I was elevated to 4.963 ng/mL (normal < 0.034 ng /mL). An ischemic evaluation was negative. CMR demonstrated normal systolic function (LVEF = 56%) with no regional wall motion abnormalities, pericardial effusion, thickening or enhancement. On T2-mapping (Panels A and B) there was regional epicardial edema (median: 69-77 msec, normal < 55 msec) and nonischemic myocardial injury on native T1 (Panel C = 1111 msec, normal 950-1050 msec) localized to the basal inferolateral segment. This was confirmed as marked epicardial fibrosis on late gadolinium enhancement imaging (Panels D and E), and regional interstitial expansion (Panel F) seen on extracellular volume fraction mapping (52%, normal <28%) in the basal inferolateral segment. All these findings support acute myocarditis according to the 2018 updated Lake Louise criteria.

A 31-year-old woman with no previous cardiac history developed chest pressure 25 days after her first dose of the Moderna COVID-19 vaccine. She had a laboratory confirmed COVID-19 infection 7 months prior. She presented to the emergency department where her COVID-19 antigen testing was negative, and her troponin I was elevated to 7.961 ng/mL (normal < 0.034 ng /mL). An ischemic evaluation was negative. CMR demonstrated normal systolic function (LVEF = 57%) with no regional wall motion abnormalities, pericardial effusion, thickening or enhancement. On T2-mapping (Panels A-C), there were skip areas of epicardial edema involving the basal inferior, basal, mid and apical lateral segments (59-66 msec, normal < 55 msec) and non-ischemic myocardial injury on native T1 mapping (Panel D = 1117-1137 msec, normal 950-1050 msec). These areas matched those where epicardial fibrosis was observed on late gadolinium enhancement imaging (Panels E-G) and interstitial expansion by extracellular volume fraction mapping (Panel H, 40-44%, normal < 28%). All these findings support acute myocarditis according to the 2018 updated Lake Louise criteria.

A 16-year-old man with no previous cardiac history developed chest pain 4 days following his first dose of the Pfizer COVID-19 vaccine. He had a laboratory confirmed COVID-19 infection 5 months prior. He presented to the emergency department where his COVID-19 antigen testing was negative, and his troponin I was elevated to 4.35 ng/mL (normal < 0.034 ng /mL). CMR demonstrated normal systolic function (LVEF = 64%) with no regional wall motion abnormalities, pericardial effusion, thickening or enhancement. On T2-mapping (Panel A), there were skip areas of epicardial edema involving the basal and mid inferior, inferolateral and anterolateral segments (56-74 msec, normal < 55 msec) and non-ischemic myocardial injury on native T1 mapping (Panel B = 1122-1128 msec, normal 950-1050 msec). These areas matched those where epicardial fibrosis was observed on late gadolinium enhancement imaging (Panels C-E) and interstitial expansion by extracellular volume fraction mapping (Panel F, 38-42%, normal < 28%). All these findings support acute myocarditis according to the 2018 updated Lake Louise criteria.

A 17-year-old women with no previous cardiac history developed chest pain 2 days following her second dose of the Pfizer COVID-19 vaccine. She did not have a known prior COVID-19 infection. She presented to the emergency department where her COVID-19 antigen testing was negative, and her troponin I was elevated to 5.41 (normal < 0.034 ng /mL). Her EKG demonstrated subtle ST elevation of the anterior limb leads. CMR demonstrated mildly decreased systolic function (LVEF=54%) with extensive skip areas of epicardial and midwall edema on T2-mapping involving the inferolateral and anterolateral segments (58-68 msec, normal < 55 msec, Panels A-C). There was corresponding non-ischemic myocardial injury on T1-mapping (Panel D=1172 msec, normal 950-1050 msec) as well as on late-gadolinium enhancement imaging (Panels E-G) in a non-coronary distribution pattern, along interstitial expansion by extracellular volume fraction mapping (Panel H, 41%, normal < 28%). All these findings support acute myocarditis according to the 2018 updated Lake Louise criteria.

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations